ASLNASLAN Pharmaceuticals Ltd

Nasdaq www.aslanpharma.com


$ 0.40 $ 0.02 (4.3 %)    

Thursday, 09-May-2024 10:40:47 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 0.4198
$ 0.42
$ 0.41 x 100
$ 0.00 x 0
$ 0.40 - $ 0.42
$ 0.39 - $ 4.69
308,923
na
51.26M
$ 1.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-announces-expansion-of-its-collaboration-with-zenyaku-to-investigate-the-biology-underlying-differential-effects-of-eblasakimab-compared-to-other-biologics

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies ...

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-reports-interim-results-from-phase-2-study-of-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients

https://www.sec.gov/Archives/edgar/data/1722926/000095017024046201/asln-ex99_1.htm 

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 hc-wainwright--co-maintains-buy-on-aslan-pharma-lowers-price-target-to-9

HC Wainwright & Co. analyst Yi Chen maintains ASLAN Pharma (NASDAQ:ASLN) with a Buy and lowers the price target from $17...

 piper-sandler-reiterates-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff reiterates ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fr...

 piper-sandler-maintains-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fro...

 piper-sandler-maintains-overweight-on-aslan-pharma-maintains-15-price-target

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and maintains $15 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION